163 related articles for article (PubMed ID: 33939714)
1. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
Chung JH; Jeong JY; Lee JY; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
PLoS One; 2021; 16(5):e0249709. PubMed ID: 33939714
[TBL] [Abstract][Full Text] [Related]
2. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
4. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
[TBL] [Abstract][Full Text] [Related]
6. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
[TBL] [Abstract][Full Text] [Related]
7. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
8. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
[TBL] [Abstract][Full Text] [Related]
9. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
11. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
14. The impact of single positive surgical margin features on biochemical recurrence after robotic radical prostatectomy.
Evren I; Hacıislamoğlu A; Ekşi M; Yavuzsan AH; Baytekin F; Çolakoğlu Y; Canoğlu D; Tugcu V
Int Braz J Urol; 2019; 45(1):45-53. PubMed ID: 30325603
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer.
Yoshida T; Matsuzaki K; Kobayashi Y; Takeda K; Nakayama M; Arai Y; Kakimoto K; Nishimura K
Int Urol Nephrol; 2012 Apr; 44(2):479-85. PubMed ID: 21822599
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
[TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
18. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
20. The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy.
Vesely S; Jarolim L; Duskova K; Schmidt M; Dusek P; Babjuk M
BMC Urol; 2014 Oct; 14():79. PubMed ID: 25277310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
